As COVID-19 becomes a business, vaccine makers confront thorny pricing questions
Bio Pharma Dive
FEBRUARY 9, 2021
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots?
Sat.Feb 06, 2021 - Fri.Feb 12, 2021
364 
The other COVID-19 health crisis in Oncology
World of DTC Marketing
FEBRUARY 11, 2021
SUMMARY : COVID-19 has caused substantial increases in the number of avoidable cancer deaths due to diagnostic and treatment delays. People who need healthcare are avoiding it because of COVID-related concerns, and in some cases, it costs them their lives. Where are healthcare companies? Recent data has revealed that the increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases, including cancer.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Jazz Pharmaceuticals to acquire GW Pharma for $7.2bn
Pharma Times
FEBRUARY 8, 2021
Jazz will add GW's plant-derived cannabinoid treatment Epidiolex to its roster
Clinical trial set to test efficacy of mixing Sputnik V and COVID-19 Vaccine AstraZeneca
BioPharma Reporter
FEBRUARY 9, 2021
Health officials in Azerbaijan have granted approval for a clinical trial to take place in that country combining Russiaâs Sputnik V vaccine with the Oxford-AstraZeneca COVID-19 shot in adults 18 years and older.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
A new startup gets Takeda's backing to take complex genetic medicines 'off the shelf'
Bio Pharma Dive
FEBRUARY 11, 2021
Ensoma Therapeutics debuts with a lucrative alliance with the Japanese pharma and an unusual way to deliver genetic medicines into the body.
Let your agency do what they do best
World of DTC Marketing
FEBRUARY 10, 2021
SUMMARY: There are some excellent digital agencies dedicated to pharma. Greater-Than-One and InTouch Solutions are just a couple. Agencies have experience in leading and developing cutting-edge digital pharma marketing solutions, but they need your help to really be effective. Agencies should never be considered vendors; they are your marketing partners.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
First look inside BioNTech's Marburg site as it starts production for COVID-19 vaccine
BioPharma Reporter
FEBRUARY 10, 2021
BioNTech announced this morning it has started the production of mRNA at its new facility in Marburg, Germany: which will become one of the largest mRNA manufacturing sites in Europe.
FDA approves Regeneron drug for rare, genetic form of high cholesterol
Bio Pharma Dive
FEBRUARY 12, 2021
The biotech set an average annual price of $450,000 for the first-of-its-kind drug, which treats a condition that affects about 1,300 people in the U.S.
Elements of a great pharma website
World of DTC Marketing
FEBRUARY 9, 2021
OPENING: Online health seekers decide whether to stay on your website within the first five seconds of landing on your homepage. They decide if your site addresses their questions after looking at 1.24 pages. Here are what I found in over two years of research with online health seekers. Remember that every health condition has particular needs and wants by their audience, but it’s clear that certain qualities overlap.
COVID-19 Long-Hauler Therapy Space Beginning to Take Shape
BioSpace
FEBRUARY 8, 2021
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
How PK Modeling Can Inform Sample Size Estimation and Dose Selection for Your Product
Camargo
FEBRUARY 10, 2021
Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Pharmacokinetics (PK) and bioequivalence (BE) studies serve as the foundation of determining the fate of drug products.
FDA clears Lilly's COVID-19 antibody cocktail for emergency use
Bio Pharma Dive
FEBRUARY 10, 2021
In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death.
AI in pharma: Can it be used in DTC?
World of DTC Marketing
FEBRUARY 7, 2021
SUMMARY: AI in the pharma industry has the ability to transform certain capabilities. DTC marketers can tap into AI to help deliver relevant messages to certain audiences, but they shouldn’t let AI do all their thinking. According to Forbes AI can be used within pharma for: Digital Therapeutics / Personalized Treatment/Behavioral Modification – This can be effectively used to assist and identify individuals to provide early insight into the condition – such as gum condition , accuratel
Triple Negative Breast Cancer Drug Development Digital Summit
pharmaphorum
FEBRUARY 10, 2021
Improving the Safety, Efficacy & Predictability of Monotherapy & Combinatorial Therapies to Fast-track the Discovery & Development of TNBC Treatments to Reach Patients in Need. This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Semaglutide Brings Significant Weight Loss in Obese Patients
NY Times
FEBRUARY 10, 2021
In a clinical trial, participants taking semaglutide lost 15 percent of their body weight, on average.
Editas names new CEO in latest executive shakeup
Bio Pharma Dive
FEBRUARY 8, 2021
James Mullen, chair of Editas' board and a former Biogen CEO, will replace Cynthia Collins in a critical year for the gene editing biotech.
Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program
BioSpace
FEBRUARY 10, 2021
The company’s head of drug development, Samit Hirawat, told analysts in a conference call last week that the decision was about working with the best drugs, particularly in a crowded field like BCMA.
How CureVac is creating a ‘broad pipeline’ of both first and second generation COVID-19 vaccines
BioPharma Reporter
FEBRUARY 8, 2021
CureVac aims to bring together expertise from both its own company and other stakeholders to provide âbroader and faster protection against current and future viral threatsâ: through collaborations with the UK Government, Bayer and GSK all announced this month.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MOVIANTO -DENNIS SPAMER, new Board Member of Movianto GERMANY
Pharma Mirror
FEBRUARY 12, 2021
The Walden Group is pleased to announce the appointment of Dennis Spamer (38) as member of the Board authorized to sign as statutory director of the company. Together with Thomas Creuzberger, who has been managing Movianto Germany since more than 20 years and Stéphane Baudry, founder and CEO of the Walden Group, Spamer shall push on the further development of the logistics specialist.
In surprise finding, Roche arthritis drug cuts risk of COVID-19 death in large UK study
Bio Pharma Dive
FEBRUARY 11, 2021
U.K. researchers running the sprawling RECOVERY trial showed that adding Actemra to standard treatment can save lives, a powerfully positive result in a long-running debate about the drug's utility in COVID-19.
Early data back J&J and AC Immune’s Alzheimer’s jab
pharmaphorum
FEBRUARY 11, 2021
Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial. . ACI-35.030, partnered with Johnson & Johnson, is designed to stimulate the body to generate antibodies against tau protein, one of the factors though to play a role in the development of AD dementia.
bluebird bio’s beta-thalassaemia gene therapy rejected by NICE
Pharma Times
FEBRUARY 12, 2021
NICE determined that there were uncertainties around the cost-effectiveness of the therapy
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA
Pharma Mirror
FEBRUARY 11, 2021
Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market. In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal a
AbbVie exploring how CRISPR gene editing can improve cell therapies
Bio Pharma Dive
FEBRUARY 10, 2021
Using technology from Caribou Biosciences, AbbVie hopes to engineer "off-the-shelf" CAR-T cells that can better withstand attacks from the immune system.
Ireland is open: The biologics boom boosting the Irish economy
pharmaphorum
FEBRUARY 12, 2021
The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming across the country. Rory Mullen, head of biopharma at Ireland’s economic development agency IDA Ireland tells pharmaphorum why business is blossoming in the Emerald Isle. With an attractive corporate tax rate and the youngest workforce in the EU, Ireland continues to be a popular destination for life science companies to settle.
Antibiotic Research UK calls for clear guidance on the use of antibiotics and COVID-19 vaccines
Pharma Times
FEBRUARY 9, 2021
Charity has urged the UK government to provide clarity on whether people receiving antibiotics can receive a COVID-19 vaccination
France ramps up COVID-19 vaccine production
BioPharma Reporter
FEBRUARY 10, 2021
Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a â300m ($363m) initiative announced on Monday.
New data on AstraZeneca vaccine add to worries over coronavirus variant from South Africa
Bio Pharma Dive
FEBRUARY 8, 2021
South Africa will use other shots in its immunization campaign after AstraZeneca's offered "minimal protection" against the variant that's spread throughout the country.
Labour accuses government of cronyism in COVID-19 contracts
pharmaphorum
FEBRUARY 9, 2021
The UK government’s massive spending on the coronavirus pandemic response has been “rife with conflicts of interest”, says the opposition Labour Party, and an independent watchdog should be set up to oversee procurement contracts. That was the message delivered by shadow Cabinet Office minister Rachel Reeves in a speech yesterday which claimed almost £2 billion of the £23.1 billion public sector spend on the pandemic went on contracts that were awarded to “Conservative friends and donors”
AZ’s Imfinzi fails to improve overall survival in head and neck cancer again
Pharma Times
FEBRUARY 8, 2021
Immunotherapy has previously failed in this therapy area
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Let's personalize your content